Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

20136,565 citationsJournal Article

Authors

Daniel D. Von Hoff · Translational Genomics Research Institute

Thomas J. Ervin · Florida Cancer Specialists & Research Institute

Francis P. Arena

E. Gabriela Chiorean · Seattle University

Jeffrey R. Infante · Sarah Cannon

Malcolm J. Moore · Princess Margaret Hospital

Thomas E. Seay

Sergei Tjulandin

Abstract

In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

Topics & Keywords

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Renal cell carcinoma treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 18, pp. 1691-1703

DOI: 10.1056/nejmoa1304369

Field-Weighted Citation Impact: 176.87